Difference between revisions of "Sunitinib (Sutent)"
m |
m |
||
| Line 20: | Line 20: | ||
*[http://chemocare.com/bio/sunitinib.asp Sunitinib (Sutent) patient drug information (Chemocare)]<ref>[http://chemocare.com/bio/sunitinib.asp Sunitinib (Sutent) patient drug information (Chemocare)]</ref> | *[http://chemocare.com/bio/sunitinib.asp Sunitinib (Sutent) patient drug information (Chemocare)]<ref>[http://chemocare.com/bio/sunitinib.asp Sunitinib (Sutent) patient drug information (Chemocare)]</ref> | ||
*[http://www.uptodate.com/contents/sunitinib-patient-drug-information Sunitinib (Sutent) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/sunitinib-patient-drug-information Sunitinib (Sutent) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/sunitinib-patient-drug-information Sunitinib (Sutent) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/sunitinib-patient-drug-information Sunitinib (Sutent) patient drug information (UpToDate)]</ref> | ||
| + | |||
| + | ==History of changes in FDA indication== | ||
| + | * 1/26/2006: Initial FDA approval: | ||
| + | # "for the treatment of [[Sarcoma | gastrointestinal stromal tumor]] after disease progression on or intolerance to [[Imatinib (Gleevec) | imatinib mesylate]]." | ||
| + | # "for the treatment of advanced [[Renal cancer | renal cell carcinoma]]." | ||
==References== | ==References== | ||
<references/> | <references/> | ||
| + | |||
| + | [[Category:Drug index]] | ||
| + | [[Category:Chemotherapy]] | ||
| + | [[Category:Oral chemotherapy]] | ||
[[Category:Kinase inhibitors]] | [[Category:Kinase inhibitors]] | ||
| Line 37: | Line 46: | ||
[[Category:Testicular cancer medications]] | [[Category:Testicular cancer medications]] | ||
[[Category:Thyroid cancer medications]] | [[Category:Thyroid cancer medications]] | ||
| + | |||
| + | [[Category:Drugs FDA approved in 2006]] | ||
Revision as of 03:03, 17 November 2014
Also known as SU11248.
General information
Class/mechanism: Tyrosine kinase inhibitor, inhibits multiple tyrosine kinases, including: vascular endothelial growth factor receptor (VEGFR1, VEGFR2 and VEGFR3), platelet-derived growth factor receptors (PDGFRα and PDGFRβ), stem cell factor receptor (KIT), Fms-like tyrosine kinase-3 (FLT3), colony stimulating factor receptor Type 1 (CSF-1R), and RET. Inhibition of these kinases disrupts angiogenesis, tumor cell signaling, and induces apoptosis.[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Sunitinib (Sutent) package insert PDF pages 26-29[1]
- Sunitinib (Sutent) patient drug information (Chemocare)[4]
- Sunitinib (Sutent) patient drug information (UpToDate)[5]
History of changes in FDA indication
- 1/26/2006: Initial FDA approval:
- "for the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate."
- "for the treatment of advanced renal cell carcinoma."
References
- Drug index
- Chemotherapy
- Oral chemotherapy
- Kinase inhibitors
- FLT3 inhibitors
- KIT inhibitors
- PDGFR inhibitors
- RET inhibitors
- VEGF inhibitors
- Hepatobiliary cancer medications
- Neuroendocrine tumor medications
- Renal cancer medications
- Sarcoma medications
- Testicular cancer medications
- Thyroid cancer medications
- Drugs FDA approved in 2006